Johnson & Johnson vs The Procter & Gamble Company: Strategic Comparison

This in-depth comparison examines Johnson & Johnson and The Procter & Gamble Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Johnson & Johnson on its own, evaluating The Procter & Gamble Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Johnson & Johnson and The Procter & Gamble Company is widest.

On the headline numbers, Johnson & Johnson reports annual revenue of $94.2B against $84.3B for The Procter & Gamble Company, while their respective market capitalizations stand at $612.8B and $390.0B. Johnson & Johnson is headquartered in United States and The Procter & Gamble Company operates from United States, and those different home markets shape how each company competes.

Johnson & Johnson: Johnson & Johnson began as a medical-products company in the nineteenth century and became a diversified healthcare giant. After the Kenvue separation, it is a more focused healthcare company centered on medicine and medical technology.

The Procter & Gamble Company: P&G does not just sell household products; it helped invent the operating system for modern consumer goods. The 1931 brand management model, the proof-led advertising style of Ivory, the technical innovation behind Tide and Pampers, and the focused brand portfolio all still shape how the company competes.

Johnson & Johnson and The Procter & Gamble Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Johnson & Johnson and The Procter & Gamble Company.

Johnson & Johnson business model: Johnson & Johnson makes money by discovering, developing, manufacturing, and selling prescription medicines and medical technologies. Innovative Medicine sells therapies in oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism. MedTech sells surgery, orthopaedics, cardiovascular, and vision products to hospitals, physicians, and healthcare systems.

The Procter & Gamble Company business model: P&G makes money by selling branded daily-use consumer products across fabric care, home care, baby care, feminine care, family care, beauty, grooming, and health care. The model depends on product superiority, marketing, retail execution, premiumization, productivity, and repeat purchase.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Johnson & Johnson stack up against those of The Procter & Gamble Company.

Johnson & Johnson competitive advantage: Johnson & Johnson's advantage comes from scale, R&D depth, global regulatory capability, major oncology and immunology franchises, MedTech breadth, and a large commercial infrastructure.

The Procter & Gamble Company competitive advantage: P&G advantage is the combination of trusted brands, R&D, retail execution, manufacturing scale, category management, and a portfolio concentrated in daily-use categories where repeat purchase matters.

Future prospects matter as much as current results. The growth strategies below explain how Johnson & Johnson and The Procter & Gamble Company each plan to expand from here.

Johnson & Johnson growth strategy: The company is investing in oncology, immunology, neuroscience, cardiovascular MedTech, electrophysiology, surgery, R&D, acquisitions, and global commercial execution.

The Procter & Gamble Company growth strategy: P&G strategy centers on product superiority, brand investment, productivity, digital commerce, supply-chain efficiency, portfolio focus, and selective reinvention of the company for the next consumer goods cycle.

A closer look at the financial trajectory of Johnson & Johnson and The Procter & Gamble Company rounds out the comparison.

Johnson & Johnson: Johnson & Johnson's FY2025 sales increased 6.0% to $94.193 billion. Net earnings rose to $26.804 billion, helped by operating performance and other income items. Innovative Medicine generated $60.401 billion in sales, while MedTech generated $33.792 billion.

The Procter & Gamble Company: P&G reported $84.284 billion of FY2025 net sales, compared with $84.039 billion in FY2024 and $82.006 billion in FY2023. Net earnings were $15.974 billion in FY2025. P&G had approximately 109,000 employees as of June 30, 2025.